Evidence map›Paper›PMID 39364726›Full record

ArticleAging cell2024

Association between prescription drugs and all-cause mortality risk in the UK population.

Jonas Morin, Yves Rolland, Heike A Bischoff-Ferrari, Alejandro Ocampo, Kevin Perez

Abstract read
In one paragraph

Article in Aging cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonas MorinEPITERNA, Epalinges, Switzerland.
Yves RollandIHU HealthAge, UMR CERPOP 1295, CHU Toulouse, Toulouse, France.
Heike A Bischoff-FerrariIHU HealthAge, UMR CERPOP 1295, CHU Toulouse, Toulouse, France.
Alejandro OcampoEPITERNA, Epalinges, Switzerland.ORCID 0000-0002-3731-3647
Kevin PerezEPITERNA, Epalinges, Switzerland.ORCID 0000-0002-1802-185X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although most drugs currently approved are meant to treat specific diseases or symptoms, it has been hypothesized that some might bear a beneficial effect on lifespan in healthy older individuals, outside of their specific disease indication. Such drugs include, among others, metformin, SGLT2 inhibitors and rapamycin. Since 2006, the UK biobank has recorded prescription medication and mortality data for over 500'000 participants, aged between 40 and 70 years old. In this work, we examined the impact of the top 406 prescribed medications on overall mortality rates within the general population of the UK. As expected, most drugs were linked to a shorter lifespan, likely due to the life-limiting nature of the diseases they are prescribed to treat. Importantly, a few drugs were associated with increased lifespans, including notably Sildenafil, Atorvastatin, Naproxen and Estradiol. These retrospective results warrant further investigation in randomized controlled trials.

Indexed as

Prescription DrugsAdultAgedFemaleHumansMaleMiddle AgedMortalityUnited KingdomPrescription Drugsagingall‐cause mortalitybiobanklifespanmedicationsmortality riskprescription drugsrepurposing

Identifiers

PMID39364726
PMCPMC11634711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.